Emergence of manic episode as a result of the treatment of antiviral agent named forcarnet in a patient used after kidney transplantation

References (4)

1. Peet M, Peters S. Drug-induced mania. Drug Saf 1995; 12(2):146-153.
2. Avery RK, Arav-Boger R, Marr KA, Kraus E, Shoham S, Lees L, et al. Outcomes in transplant recipients treated with foscarnet for ganciclovir- resistant or refractory cytomegalovirus infection. Transplantation 2016; 100(10):74-80.
3. Meaney CJ, Arabi Z, Venuto RC, Consiglio JD, Wilding GE, Tornatore KM. Validity and reliability of a novel immunosuppressive adverse effects scoring system in renal transplant recipients. BMC Nephrol 2014; 15:88. Dell'Osso B, Prati G, Palazzo MC, Rumi MG, Caval- laro F, Aghemo A, et al. Predictors of psychopatho- logical outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis. J Interferon Cytokine Res 2013; 33: 9-14.
4. Mahajan S, Avasthi A, Grover S, Chawla YK. Role of baseline depressive symptoms in the develop- ment of depressive episode in patients receiving antiviral therapy for hepatitis C infection. J Psycho- som Res 2014; 77: 109-115. Whitley RW. The use of antiviral drugs during the neonatal period. Clin Perinatol 2013; 2012; 39(1):69-81.